USA

The NextAR Shoulder application forms part of Medacta’s broader NextAR Augmented Reality Surgical Platform, which supports multiple applications across joint replacement and spine surgery.

The collaboration will enhance the company’s ability to analyze complex datasets, identify promising drug candidates, and significantly reduce the time required to bring medications to patients.

Peak XV Partners leads investment round, with participation from Define Ventures and previous backers.

The agreement also includes potential clinical, regulatory, and commercial milestone payments that could raise the total value to USD7 billion,

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

Under the agreement, Stereotaxis will pay USD20 million upfront, with up to an additional USD25 million tied to milestone-based payments.

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

AVS has developed the Pulse IVL system, which uses pressurised sound waves delivered through a balloon catheter to remove calcium deposits in patients with calcified peripheral artery disease (PAD).

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.